Becton, Dickinson and Company $BDX Stock Holdings Cut by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 679,261 shares of the medical instruments supplier’s stock after selling 26,852 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.25% of Becton, Dickinson and Company worth $121,588,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of BDX. Maryland Capital Advisors Inc. raised its position in shares of Becton, Dickinson and Company by 13,900.0% in the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 139 shares during the period. Meeder Asset Management Inc. grew its holdings in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 102 shares during the period. Main Street Group LTD acquired a new position in Becton, Dickinson and Company during the first quarter valued at approximately $29,000. Bell Investment Advisors Inc acquired a new position in Becton, Dickinson and Company during the second quarter valued at approximately $29,000. Finally, Kelleher Financial Advisors bought a new stake in Becton, Dickinson and Company in the second quarter valued at approximately $30,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on BDX shares. Wells Fargo & Company increased their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Jefferies Financial Group reissued a “buy” rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Wolfe Research started coverage on shares of Becton, Dickinson and Company in a report on Tuesday, October 20th. They issued an “outperform” rating for the company. Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Finally, Piper Sandler raised their price objective on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $185.07.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 6,907 shares of company stock valued at $1,269,128 over the last quarter. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE BDX opened at $198.77 on Tuesday. The business has a 50 day simple moving average of $186.71 and a 200 day simple moving average of $170.25. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $200.47. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock has a market cap of $54.77 billion, a price-to-earnings ratio of 59.87, a PEG ratio of 13.16 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period last year, the company posted $3.68 EPS. The business’s quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.